Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Mortality
Hospitalization
Serious outcomes
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Casirivimab/imdevimab  COVID-19 treatment studies for Casirivimab/i..  C19 studies: Casirivimab/i..  Casirivimab/i..   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 casirivimab/imdevimab studies
00.250.50.7511.251.51.752+Regeneron (RCT)38%0.62 [0.29-1.33]recov. time92 (n)91 (n)Improvement, RR [CI]TreatmentControlRegeneron (RCT)71%0.29 [0.17-0.48]hosp./death18/1,35562/1,341Weinreich (RCT)67%0.33 [0.03-3.17]death1/1,3553/1,341Webb98%0.02 [0.00-0.27]death0/11557/5,536Tau​2 = 0.39; I​2 = 58.8%Early treatment69%0.31 [0.13-0.74]19/2,917122/8,30969% improvementHorby (RCT)6%0.94 [0.86-1.03]death944/4,8391,026/4,946Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment6%0.94 [0.86-1.03]944/4,8391,026/4,9466% improvementRegeneron (RCT)94%0.06 [0.00-1.10]symp. case0/1868/223Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP94%0.06 [0.00-1.10]0/1868/22394% improvementO'Brien (DB RCT)89%0.11 [0.01-2.06]hosp./ER0/7534/752Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP89%0.11 [0.01-2.06]0/7534/75289% improvementAll studies66%0.34 [0.15-0.76]963/8,6951,160/14,23066% improvement7 casirivimab/imdevimab COVID-19 studiesc19regn.com Sep 26, 2021Tau​2 = 0.64; I​2 = 82.6%; Z = 2.62Effect extraction pre-specifiedFavors casiri/imdevimabFavors control 00.250.50.7511.251.51.752+Weinreich (RCT)67%0.33 [0.03-3.17]1/1,3553/1,341Improvement, RR [CI]TreatmentControlWebb98%0.02 [0.00-0.27]0/11557/5,536Tau​2 = 2.75; I​2 = 62.2%Early treatment92%0.08 [0.00-1.53]1/1,47060/6,87792% improvementHorby (RCT)6%0.94 [0.86-1.03]944/4,8391,026/4,946Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment6%0.94 [0.86-1.03]944/4,8391,026/4,9466% improvementAll studies76%0.24 [0.03-2.14]945/6,3091,086/11,82376% improvement3 casirivimab/imdevimab COVID-19 mortality resultsc19regn.com Sep 26, 2021Tau​2 = 2.75; I​2 = 77.4%; Z = 1.27Favors casiri/imdevimabFavors control 00.250.50.7511.251.51.752+Webb91%0.09 [0.01-0.63]hosp.1/115538/5,536Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment91%0.09 [0.01-0.63]1/115538/5,53691% improvementAll studies91%0.09 [0.01-0.63]1/115538/5,53691% improvement1 casirivimab/imdevimab COVID-19 hospitalization resultc19regn.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.42Favors casiri/imdevimabFavors control 00.250.50.7511.251.51.752+Regeneron (RCT)71%0.29 [0.17-0.48]hosp./death18/1,35562/1,341Improvement, RR [CI]TreatmentControlWeinreich (RCT)67%0.33 [0.03-3.17]death1/1,3553/1,341Webb98%0.02 [0.00-0.27]death0/11557/5,536Tau​2 = 0.81; I​2 = 48.7%Early treatment82%0.18 [0.04-0.72]19/2,825122/8,21882% improvementHorby (RCT)6%0.94 [0.86-1.03]death944/4,8391,026/4,946Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment6%0.94 [0.86-1.03]944/4,8391,026/4,9466% improvementO'Brien (DB RCT)89%0.11 [0.01-2.06]hosp./ER0/7534/752Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP89%0.11 [0.01-2.06]0/7534/75289% improvementAll studies70%0.30 [0.10-0.87]963/8,4171,152/13,91670% improvement5 casirivimab/imdevimab COVID-19 serious outcomesc19regn.com Sep 26, 2021Tau​2 = 0.84; I​2 = 86.8%; Z = 2.22Effect extraction pre-specifiedFavors casiri/imdevimabFavors control 00.250.50.7511.251.51.752+Regeneron (RCT)48%0.52 [0.25-1.07]10/18623/223Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP48%0.52 [0.25-1.07]10/18623/22348% improvementAll studies48%0.52 [0.25-1.07]10/18623/22348% improvement1 casirivimab/imdevimab COVID-19 case resultc19regn.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.78Favors casiri/imdevimabFavors control 00.250.50.7511.251.51.752+O'Brien (DB RCT)69%0.31 [0.17-0.55]viral time753 (n)752 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP69%0.31 [0.17-0.55]0/7530/75269% improvementAll studies69%0.31 [0.17-0.55]0/7530/75269% improvement1 casirivimab/imdevimab COVID-19 viral clearance resultc19regn.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 3.92Favors casiri/imdevimabFavors control 00.250.50.7511.251.51.752+Regeneron (RCT)38%0.62 [0.29-1.33]recov. time92 (n)91 (n)Improvement, RR [CI]TreatmentControlRegeneron (RCT)71%0.29 [0.17-0.48]hosp./death18/1,35562/1,341Weinreich (RCT)67%0.33 [0.03-3.17]death1/1,3553/1,341Tau​2 = 0.07; I​2 = 25.5%Early treatment62%0.38 [0.22-0.67]19/2,80265/2,77362% improvementHorby (RCT)6%0.94 [0.86-1.03]death944/4,8391,026/4,946Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment6%0.94 [0.86-1.03]944/4,8391,026/4,9466% improvementRegeneron (RCT)94%0.06 [0.00-1.10]symp. case0/1868/223Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP94%0.06 [0.00-1.10]0/1868/22394% improvementO'Brien (DB RCT)89%0.11 [0.01-2.06]hosp./ER0/7534/752Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP89%0.11 [0.01-2.06]0/7534/75289% improvementAll studies57%0.43 [0.20-0.93]963/8,5801,103/8,69457% improvement6 casirivimab/imdevimab COVID-19 Randomized Controlled Trialsc19regn.com Sep 26, 2021Tau​2 = 0.49; I​2 = 81.3%; Z = 2.15Effect extraction pre-specifiedFavors casiri/imdevimabFavors control 00.250.50.7511.251.51.752+Weinreich (RCT)67%0.33 [0.03-3.17]1/1,3553/1,341Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment67%0.33 [0.03-3.17]1/1,3553/1,34167% improvementHorby (RCT)6%0.94 [0.86-1.03]944/4,8391,026/4,946Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment6%0.94 [0.86-1.03]944/4,8391,026/4,9466% improvementAll studies6%0.94 [0.87-1.02]945/6,1941,029/6,2876% improvement2 casirivimab/imdevimab COVID-19 RCT mortality resultsc19regn.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.57Favors casiri/imdevimabFavors control 00.250.50.7511.251.51.752+Webb98%0.02 [0.00-0.27]death0/11557/5,536Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment98%0.02 [0.00-0.27]0/11557/5,53698% improvementO'Brien (DB RCT)89%0.11 [0.01-2.06]hosp./ER0/7534/752Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP89%0.11 [0.01-2.06]0/7534/75289% improvementAll studies96%0.04 [0.01-0.31]0/86861/6,28896% improvement2 casirivimab/imdevimab COVID-19 peer reviewed trialsc19regn.com Sep 26, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 3.10Effect extraction pre-specifiedFavors casiri/imdevimabFavors control 00.250.50.7511.251.51.752+Regeneron (RCT)38%0.62 [0.29-1.33]recov. time92 (n)91 (n)Improvement, RR [CI]TreatmentControlRegeneron (RCT)54%0.46 [0.19-1.13]recov. time92 (n)91 (n)Regeneron (RCT)71%0.29 [0.17-0.48]hosp./death18/1,35562/1,341Regeneron (RCT)70%0.30 [0.13-0.68]hosp./death7/73624/748Regeneron (RCT)29%0.71 [0.60-0.85]recov. time1,355 (n)1,341 (n)Regeneron (RCT)29%0.71 [0.60-0.85]recov. time736 (n)748 (n)Weinreich (RCT)67%0.33 [0.03-3.17]death1/1,3553/1,341Weinreich (RCT)39%0.61 [0.06-5.83]death1/7363/1,341Weinreich (RCT)71%0.29 [0.17-0.48]hosp./death18/1,35562/1,341Weinreich (RCT)70%0.30 [0.13-0.68]hosp./death7/73624/748Weinreich (RCT)29%0.71 [0.60-0.85]recov. time1,355 (n)1,341 (n)Weinreich (RCT)29%0.71 [0.60-0.85]recov. time736 (n)748 (n)Webb98%0.02 [0.00-0.27]death0/11557/5,536Webb91%0.09 [0.01-0.63]hosp.1/115538/5,536Horby (RCT)6%0.94 [0.86-1.03]death944/4,8391,026/4,946Horby (RCT)0%1.00 [0.89-1.13]ventilation479/4,556487/4,642Horby (RCT)20%0.80 [0.70-0.91]death396/1,633451/1,520Horby (RCT)12%0.88 [0.73-1.06]ventilation189/1,599200/1,484Regeneron (RCT)94%0.06 [0.00-1.10]symp. case0/1868/223Regeneron (RCT)48%0.52 [0.25-1.07]cases10/18623/223O'Brien (DB RCT)89%0.11 [0.01-2.06]hosp./ER0/7534/752O'Brien (DB RCT)81%0.19 [0.10-0.35]symp. case11/75359/752O'Brien (DB RCT)62%0.38 [0.23-0.61]recov. time753 (n)752 (n)O'Brien (DB RCT)69%0.31 [0.17-0.55]viral time753 (n)752 (n)casirivimab/imdevimab COVID-19 outcomesc19regn.com Sep 26, 2021Favors casiri/imdevimabFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit